Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Abstract 1979: Low CD47 expression in specific populations of tumor macrophage fusion cells in blood correlates with progressive disease in metastatic cancers
Muthuraj, Sonia, Chumsri, Saranya , Tsai, Susan, Tang, Cha-Mei, Cristofanilli, Massimo , Bergan, Raymond C. , Tang, Cha‐Mei , Adams, Daniel L.

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 1979-1979

10.1158/1538-7445.am2025-1979 Get It

Abstract Tumor associated macrophages are known to fuse with cancer cells resulting in the formation of a cellular phenomenon called tumor-macrophage fusion cells (TMFCs). TMFCs are a highly aggressive cell subtype that may move into circulation, evade immune surveillance, and possibly aid in seeding of metastatic sites. The formation of TMFCs involves CD47, a ubiquitous surface receptor that acts as a “don’t eat me” signal, interacting with the macrophage protein SIRPa, a down regulator of phagocytosis, and syncytin-1, a mediator of hyperploidy cancer fusion. In this analysis, we isolated circulating TMFCs from the blood of n=39 metastatic cancer patients (pts) to evaluate the expressions of CD47, SIRPa and syncytin-1 as it relates to stable or progressive disease via 30 day imaging by PET scan. We conducted a prospective pilot study of n=39 pts with pathologically confirmed metastatic breast (n=17), prostate (n=7), pancreas (n=7), or colon (n=8) cancer receiving standard of care systemic therapy. We isolated TMFCs from 7.5ml peripheral blood using a CellSieve microfilter, and stained with CD47, SIRPa, & syncytin-1. TMFCs were identified based on large cell size (>30 µm) & multinucleated structure, and were categorized into 4 distinct subtypes: A) >2 distinct non-contacting nuclei within a TMFC, B) 2 distinct non-contacting nuclei, C) 2 contacting nuclei, D) a single multinucleated nuclei. CD47, SIRPa, and syncytin-1 expressions were categorized as negative, low, or high. TMFCs subtypes and marker expressions were compared to pts’ clinical status (i.e. progressive, stable or responding) at first available PET/CT scans after blood draw (∼45 days). TMFCs were identified in 72% of pts (n=28/39), average 8 cells/sample, and ranged 1-77 cells. Of the TMFCs, 12% were subtype A, 11% as B, 11% as C, and 66% as D. CD47 expression was seen in 100% of TMFs, with low expression in 39% of subtype A cells, 58% subtype B, 39% subtype C, & 62% subtype D. Notably, CD47 was significantly lower (p=0.010) in subtype B than other groups. Further, the expression of syncytin-1 in subtype B cells was significantly lower (p=0.02) than in other subtypes, and subtype D cells had 75% higher syncytin-1 localized to the nuclear regions. No correlations were found in the SIRPa expression and subtypes. Interestingly, progressing pts had 200% more TMFCs, more subtype B (83%), and significantly lower (p<0.001) CD47 expressing TMFCs than non-progressing pts. In this pilot study on the expression profiles of circulating TMFCs, it appears that specific subtypes of TMFC with low CD47 expression may be associated with progressive disease. Interestingly, this contrasts existing studies on primary tumors which often correlate higher CD47 with more aggressive cancers. This finding suggests that low CD47 cancer cells circulate blood in some pts with progressing disease and may be pertinent to efforts targeting CD47 in cancer. Citation Format: Sonia Muthuraj, Massimo Cristofanilli, Saranya Chumsri, Susan Tsai, Raymond C. Bergan, Cha-Mei Tang, Daniel L. Adams. Low CD47 expression in specific populations of tumor macrophage fusion cells in blood correlates with progressive disease in metastatic cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1979.
Abstract 2429: A multi-modal learning framework to integrate digital pathology image and multi-omics data in breast cancer
Prodduturi, Naresh, Weinshilboum, Richard, Klee, Eric W. , Wang, Liewei , Goetz, Matthew P. , Tang, Xiaojia , Tizhoosh, Hamid R. , Thompson, Kevin J. , Giridhar, Karthik V. , Boughey, Judy C. , Goetz, Matthew P. , Suman, Vera J. , Kalari, Krishna R.

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2429-2429

10.1158/1538-7445.am2025-2429 Get It

Abstract Deep learning has advanced digital pathology and multi-omics data analysis. However, there is still a critical need to integrate these modalities to better understand complex diseases. Deep learning models, such as Prov-Gigapath, a state-of-the-art pathology foundation model, have been developed for analyzing whole-slide images (WSI). Our previously published deep-learning framework, OmicsFootPrint (OFP), transforms high-dimensional multi-omics data into intuitive genomically-arranged circular images and utilizes transfer learning to overcome the challenges of high-dimensional, low-sample-size data. In this study, we aimed to combine WSI and multi-omics data to develop a framework capable of distinguishing between invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), which is clinically significant as it may help explain differential responses to therapies, such as tamoxifen versus letrozole. We enhanced the performance of our OFP model by dividing each multi-omics circular image (1024x1024x3 pixels) into 16 equal-sized patches (256x256x3 pixels). Each patch was trained using a separate EfficientNetV2 architecture with pre-trained ImageNet weights. The probability outcomes from these 16 models were subsequently combined through a meta-learner model using the AutoGluon framework. Concurrently, WSI images corresponding to the same patients were independently trained, maintaining consistent train/validation/test splits. The Prov-Gigapath model, which was trained using a dataset from the Providence Health System, was employed to extract patch-level embeddings from the WSI data. These embeddings were fine-tuned using a LongNet-based masked autoencoder to predict outcomes. Finally, predictions from the OFP model and the WSI-based Prov-Gigapath model were integrated through a meta-learner, preserving the original train/validation/test split. Model performances (AUC) were evaluated using the held-out test set. The gold standard used for the analysis was histological identification of IDC versus ILC, against which the performance of omics data alone, WSI data alone, and the multi-modal integration approach were compared. We evaluated our integrated model as a proof-of-concept using The Cancer Genome Atlas (TCGA) breast cancer cohort, comprising 92 ILC and 391 IDC samples. Multi-omics data, including gene expression, microRNA, copy number variation, and RPPA, were analyzed using the OFP framework, while WSI data were processed using the Prov-Gigapath method. The results demonstrated that the multi-modal integration approach significantly outperformed individual modalities, achieving an AUC of 0.98 compared to 0.87 for OFP (original), 0.95 for OFP (16-patches), and 0.92 for WSI. Integrating WSI and multi-omics data improves predictive accuracy, significantly improving the classification of breast cancer subtypes over histology alone. Citation Format: Naresh Prodduturi, Xiaojia Tang, Hamid R. Tizhoosh, Kevin J. Thompson, Richard Weinshilboum, Karthik V. Giridhar, Judy C. Boughey, Eric W. Klee, Liewei Wang, Matthew P. Goetz, Vera Suman, Krishna R. Kalari. A multi-modal learning framework to integrate digital pathology image and multi-omics data in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2429.
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
Tesfay, Mulu Z. , Ferdous, Khandoker Usran, Shelton, Randal S., Mustafa, Bahaa , Simões, Camila , Moaven, Moaven, Roberts, Lewis R. , Cannon, Martin J. , Bolni, Nagalo, Roberts, Lewis R , Cios, Aleksandra , Post, Steven R. , Kelly, Thomas J. , Borad, Mitesh J. , Basnakian, Alexei G.

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 945-945

10.1158/1538-7445.am2025-945 Get It

The global burden of hepatocellular carcinoma (HCC) continues to rise, driven by increasing metabolic risk factors such as nonalcoholic fatty liver disease, obesity, and type II diabetes. Patients with advanced HCC have limited therapeutic options and a dismal prognosis. While recent advancements in combination therapies—including immune checkpoint blockade (ICB) with anti-PD-1/PD-L1 and anti-CTLA-4 agents and anti-angiogenics—have improved survival for some, up to 80% of patients fail to respond, underscoring an unmet need for new strategies. Emerging data indicate a strong association between increased tumor-infiltrating lymphocytes (TILs) and better responses in ICB-treated HCC, suggesting TIL enhancement as a promising approach. However, HCC’s inherent low immunogenicity and immunosuppressive tumor microenvironment (TME) limit the efficacy of current TIL-promoting strategies. Here, we demonstrate that low-dose intratumoral immunotherapy using the trivalent MMR vaccine—composed of live attenuated measles, mumps, and rubella viruses—modulates TME immune infiltration, increases cytotoxic T cell frequency, and delays tumor growth in multiple murine HCC models. Importantly, intratumoral or systemic MMR administration in combination with dual ICB (anti-mPD-1/anti-mCTLA-4) significantly prolongs survival, promoting tumor-specific and memory immune responses in both subcutaneous and orthotopic HCC models. These findings reveal a unique mechanism of vaccine-induced anti-tumor activity, highlighting MMR as a viable, globally accessible option for enhancing immune responses in advanced HCC therapy. Citation Format: Mulu Z. Tesfay,Aleksandra Cios,Khandoker U. Randal S. Shelton,Bahaa Mustafa,Camila C. Simoes,Steven Post,Thomas Kelly,Moaven Moaven,Lewis R. Roberts,Mitesh J. Borad,Martin J. Cannon,Alexei Basnakian,Nagalo Bolni. Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 945.
Abstract 1912: Immune and molecular markers in benign breast disease predict risk of node-positive breast cancer
Rossi, Matilde , Cruz-Reyes, Nicole , Navarro, Trista, McCauley, Bryan M. , Stallings‐Mann, Melody , Vierkant, Robert A. , Winham, Stacey J. , Sherman, Mark E. , Degnim, Amy C. , Radisky, Derek C.

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 1912-1912

10.1158/1538-7445.am2025-1912 Get It

Abstract Background: Breast cancer (BC) remains a leading health concern worldwide and is often undetected until it metastasizes, limiting treatment options and worsening prognosis. Early detection of molecular and immune markers in benign breast disease (BBD) could identify women at elevated risk of developing invasive, node-positive BC, enabling targeted surveillance and prevention efforts. Building on this premise, we investigated the immune and molecular landscape of BBD biopsies preceding BC development to enhance risk stratification and inform preventive strategies. Methods: Utilizing the Mayo Clinic BBD cohort, we conducted a case-control study comparing women who developed node-positive BC following their BBD biopsy (cases; n=8) to those who remained cancer-free (controls; n=11), matched on patient age and biopsy date. Differential gene expression was assessed using the NanoString nCounter system to identify differentially expressed genes between cases and controls. We developed a multiplex immunofluorescence (MxIF) approach using the Opal system by Akoya Biosciences for comprehensive marker detection in formalin-fixed, paraffin-embedded (FFPE) tissue samples. Digitized images were segmented for cell phenotyping, and spatial relationships of immune cells were analyzed and compared between cases and controls. Results: Our findings revealed significantly increased expression levels of immunosuppressive genes in the case group, including CD48, CD84, IL-32, and LAIR1. Immunohistochemical analyses showed that controls exhibited higher frequencies of CD68+ (macrophages), CD11c+ (M1 macrophages), and CD206+ (M2 macrophages) cells compared to cases. Notably, controls had a significant increase in CD68+CD11c+ cells, indicative of a pro-inflammatory, antitumorigenic M1 macrophage polarization. Furthermore, our MxIF analyses provided novel insights into spatial biomarker localization, enhancing prognostic accuracy. Conclusions: The decreased numbers of immune cells and increased expression of immunosuppressive genes in BBD biopsies may be associated with an elevated risk of developing axillary node-positive BC. These findings emphasize the importance of dissecting molecular and immune interactions in BBD for risk assessment. Our results have the potential to improve individualized risk stratification, leading to more targeted surveillance and informed screening. This research not only contributes to our understanding of BC pathogenesis but also opens avenues for developing novel preventive strategies, potentially reducing BC incidence and mortality through early intervention. Citation Format: Matilde Rossi, Nicole Cruz-Reyes, Trista Navarro, Melody L. Stallings-Mann, Bryan M. McCauley, Robert A. Vierkant, Stacey J. Winham, Mark E. Sherman, Amy C. Degnim, Derek C. Radisky. Immune and molecular markers in benign breast disease predict risk of node-positive breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1912.
Abstract 2274: Implications of multiple myeloma polygenic risk scores (PRS) for MGUS
Macauda, Angelica , Allmer, Cristine, Moonen, Danelle, Normann, Aaron D., Brown, Elizabeth E. , Murray, David , Kumar, Shaji, Vachon, Celine M. , Clay‐Gilmour, Alyssa , Boddicker, Nicholas , Cook, Joselle , Baughn, Linda B. , Rajkumar, S. Vincent , Braggio, Esteban , Slager, Susan L. , Kumar, Shaji , Vachon, Celine M.

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2274-2274

10.1158/1538-7445.am2025-2274 Get It

Genome-wide association studies (GWAS) of multiple myeloma (MM) in individuals of genetic European ancestry (EA) have identified 35 susceptibility loci. Co-heritability analyses have revealed a strong genetic correlation between MM and its precursor condition, monoclonal gammopathy of undetermined significance (MGUS). Previous research validated the association between a polygenic risk score (PRS) based on 23 MM risk loci and the risk of MGUS. Went and colleagues recently reported 12 new MM risk loci. We constructed a MM-PRS using all 35 MM risk variants and assessed its association with MGUS. Additionally, among individuals with MGUS, we assessed associations of MM-PRS with established prognostic factors [M-protein (<0.2 g/dL; 0.2-1.5 g/dL; >1.5 g/dL); isotype (IgG, IgA, IgM); free light chain (FLC) ratio (Normal (0.26-1.65), Abnormal (<0.26 or >1.65))]. Our study population included 1,723 individuals with MGUS seen at Mayo Clinic, Rochester, MN and 14,175 controls from the Mayo Clinic Biobank who lived in the 27-county region around Rochester, MN, and screened negative for MGUS using MALDI-TOF MS. The majority of MGUS patients and controls were of EA. We used logistic or multinomial regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs). All models were adjusted for age, sex, and the first three principal components. The MM-PRS was significantly associated with MGUS when assessed continuously (OR, 1.28 per standard deviation (SD); 95% CI, 1.22-1.35). When comparing to the middle quintile of the MM-PRS distribution, individuals in the highest quintile had 1.41-fold increased risk of MGUS (95% CI, 1.21-1.64), and individuals in the lowest quintile had 0.68 decreased risk of MGUS (95% CI, 0.57-0.81). Of the 35 SNPs evaluated, 27 demonstrated consistent directions of effect for risk of MGUS with published risk estimates for MM. The effect of MM-PRS differed by isotype (P = 2.2 x 105), with higher MM-PRS associated with IgA MGUS (OR, 1.40 per SD; 95% CI, 1.08-1.81) and a lower MM-PRS associated with IgM (OR, 0.66 per SD; 95% CI, 0.52-0.84) compared to IgG MGUS. The MM-PRS was higher in MGUS patients with M-protein > 1.5 g/dL compared to M-protein of size 0.2-1.5 g/dL, although not statistically significant (OR, 1.41 per SD; 95% CI, 0.95-2.08); there were no differences in the MM-PRS between MGUS patients with M-protein size <0.2 g/dL compared to 0.2-1.5 g/dL (OR, 1.01 per SD;95% CI, 0.81-1.26). There were also no differences in MM-PRS by FLC ratio, (OR, 0.95 per SD; 95% CI, 0.852-1.10 for abnormal vs. normal). Our findings of an association of the MM-PRS with risk of MGUS provides further evidence for shared heritability between MGUS and MM. Future studies are needed to examine whether the expanded MM-PRS adds to existing models for MGUS progression. Citation Format: Angelica Macauda, Alyssa Clay-Gilmour, Cristine Allmer, Danelle Moonen, Aaron D. Normann, Nicholas J. Boddicker, Joselle M. Cook, Linda Baughn, Elizabeth E. Brown, Vincent S. Rajkumar, Esteban Braggio, David L. Murray, Susan L. Slager, Shaji Kumar, Celine M. Vachon. Implications of multiple myeloma polygenic risk scores (PRS) for MGUS [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2274.
Abstract 3250: Tumor-independent monitoring of minimal residual disease in multiple myeloma using cfDNA fragmentomics
Abelman, Dor , Eagles, Jenna , Wong, Aimée A., Shah, Saumil , Bridges, Sarah, White, Darrell , Song, Kevin , Murugesan, Alli , Reiman, Tony , Trudel, Suzanne , Wong, Aimee, Pedersen, Stephanie , Prokopec, Stephenie D. , Scott, David S., Sandhu, Irwindeep , Braggio, Esteban , Pugh, Trevor J.

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 3250-3250

10.1158/1538-7445.am2025-3250 Get It

Abstract Introduction: Monitoring minimal residual disease (MRD) is critical in multiple myeloma (MM) to predict outcomes and guide therapy. Traditional bone marrow (BM) aspirates for MRD detection are invasive and limited by sample quality. We therefore explored cell-free DNA (cfDNA) fragmentation as a less invasive alternative for MRD detection. Methods: We performed 30-40X whole-genome sequencing (WGS) on peripheral blood cfDNA from 45 MM patients, collecting baseline (n = 45) and follow-up samples (n = 98) from eight Canadian sites (M4 and IMMAGINE studies) and one U.S. site (SPORE study), plus 25 healthy controls. Samples were collected post-induction therapy (n = 13), 100 days post-autologous stem cell transplantation (ACST, n = 36), and during maintenance therapy (n = 49). Multiparameter flow cytometry (MFC) MRD testing was conducted on 77 samples. We evaluated insert size metrics and MM-specific chromatin accessibility (from Ordoñez et al., 2020) using Griffin (described in Doebley et al., 2022). Results: Baseline samples had a higher proportion of short fragments (20-150 bp) than follow-up samples (p = 0.0037) and healthy controls (p = 0.019). A fragment score (FS) based on weighted fragment distribution (per Vessies et al., 2022) was highest at baseline (mean = -0.384), followed by MRD-positive (mean = -0.495) and MRD-negative (mean = -0.550) samples. MRD-negative FS was lower than baseline samples (p < 0.001) but higher than healthy controls (mean = -0.639; p = 0.016). Baseline samples had lower coverage at MM-specific chromatin regions than MRD timepoints (p < 0.05; baseline mean = 0.982; MRD-positive = 0.989; MRD-negative = 0.994; healthy = 0.993), suggesting higher transcriptional activity pre-treatment. MRD-negative samples had higher coverage than MRD-positive cases (p < 0.01). Using logistic regression, we assessed the predictive performance of FS and coverage at MM-specific sites. FS alone achieved an AUC of 0.632 (sensitivity [SN] 39.4%, specificity [SP] 92.1%, accuracy [AC] 67.6%). Coverage yielded an AUC of 0.681 (SN 75.8%, SP 60.5%, AC 67.6%). Combining FS and coverage at MM sites improved performance (AUC = 0.734; SN 48.5%, SP 92.1%, AC 71.8%). We next evaluated whether adjusting the BM tumor cell percentage cutoff by MFC could improve performance. At 0.017% (1 in 5, 789 cells) for MRD positivity, the combined model’s accuracy reached 83% with an AUC of 0.757 (SN 17%, SP 97%). Conclusions: cfDNA fragmentomic analysis achieved high specificity (92-97%) in detecting MRD, providing a less invasive alternative to facilitate serial monitoring. While sensitivity remains an area for improvement, the high specificity of cfDNA makes it valuable for confirming MRD negativity and reducing invasive procedures. Future efforts aim to enhance sensitivity by integrating additional fragmentomic features. Citation Format: Dor D. Abelman, Jenna Eagles, Aimee Wong, Saumil Shah, Stephanie Pedersen, Stephenie Prokopec, David S. Scott, Sarah Bridges, Darrell White, Irwindeep Sandhu, Kevin Song, Esteban Braggio, Alli Murugesan, Anthony Reiman, Suzanne Trudel, Trevor J. Pugh. Tumor-independent monitoring of minimal residual disease in multiple myeloma using cfDNA fragmentomics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3250.
How Does the Mandible Age? Comprehensive Artificial Intelligence–Assisted Shape Analysis in the White Population
Hussein, S.H., Rames, Jess D. , Shehab, Abdallah A. , Pazelli, Alexandre Meira, Sears, Victoria A. , Wentworth, Adam, Morris, Jonathan M. , Pazelli, Alexandre M., Sharaf, Basel

Plastic and Reconstructive Surgery - Global Open | April 21, 2025 | Volume: 13 | Issue: 4 | Pages: e6650

10.1097/gox.0000000000006650 | PMID 40264908 Get It

Background: Mandible contour significantly influences facial appearance, framing the lower facial silhouette. Redefining mandibular contour is key for facial and neck rejuvenation. Yet, there is limited facial aging research across different lifespans and sexes. Here, we utilize artificial intelligence and advanced 3-dimensional (3D) analysis to elucidate mandibular aging patterns in male and female subjects. Methods: A retrospective analysis of facial computed tomography scans in White patients was conducted, categorizing subjects into 3 age groups (20–79 y) and stratifying them by sex. Artificial intelligence–assisted segmentation into 3D mandibles was done in Mimics v.25, and statistical shape modeling was used to create an average mandible for each group. Volume and linear measurements were assessed via 3D overlays. Results: Analysis of 280 mandibles demonstrated statistically significant aging changes in both sexes. Ramus height showed a marked decrease with age, by approximately 5.3 mm in women and 4.2 mm in men (P < 0.001). Interrami and intercondylar widths increased by a mean of 4–5 mm (P < 0.01). Women exhibited an increase in mandibular angle (P < 0.01), and bony resorption over the chin compared to men, who exhibited concentrated bone resorption at the gonion projection. Conclusions: Mandibular aging, independent of tooth loss, exhibits specific bone remodeling patterns by sex. Posteriorly, mandibular widths increase in both sexes, whereas ramus height decreases. Women experience more resorption at the anterior alveolar surface and chin than men. Statistical shape modeling effectively visualizes these patterns on a population level, bridging the gap between traditional aging research and current understanding.
Late Relapse After Autologous Hematopoietic Stem Cell Transplantation in AQP4-IgG–Positive NMOSD
Vorasoot, Nisa , Bush, Melissa L., Jenkins, Sarah M. , Jitprapaikulsan, Jiraporn , Fryer, James P., Irani, Sarosh R. , Pittock, Sean J. , Pittock, S J , Irani, Sarosh R , Vorasoot, Nisa , Blackburn, Kyle , Nguyen, Linda , Bush, Melissa L., Flanagan, Eoin P.

JAMA Network Open | April 21, 2025 | Volume: 8 | Issue: 4 | Pages: e255989

10.1001/jamanetworkopen.2025.5989 | PMID 40257801 Get It

This case series examines long-term outcomes for 2 aquaporin-4-IgG (AQP4-IgG)–positive patients with neuromyelitis optica spectrum disorder (NMOSD) who underwent autologous hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen and rituximab.
PRO MELD: MELD is the best method of prioritization for liver transplantation
Charu, Vivek , Kwong, Allison J. , Kwong, Allison , Kim, W. Ray

Liver Transplantation | April 21, 2025 | Volume: 31 | Issue: 10 | Pages: 1298-1302

10.1097/lvt.0000000000000626 | PMID 40257300 Get It

Safe Use of Regional Anesthesia in a Patient With Hypertrophic Olivary Degeneration: A Case Report
Thiele, Cameron M., VanderWielen, Beth A.

A&A Practice | April 21, 2025 | Volume: 19 | Issue: 4 | Pages: e01960

10.1213/xaa.0000000000001960 | PMID 40257128 Get It

Hypertrophic olivary degeneration (HOD) is a rare condition characterized by degeneration and hypertrophy of the inferior olivary nucleus (ION) in the brainstem. This case report presents a 39-year-old woman with HOD undergoing left total shoulder arthroplasty. Despite long-standing concerns about regional anesthesia in patients with central nervous system disorders, an interscalene catheter was placed using ultrasound and nerve stimulation guidance. The patient experienced effective analgesia without new neurologic deficits. This report highlights the safe use of regional anesthesia in patients with HOD and underscores the need for individualized anesthetic management and further research to establish clear guidelines.